Compare ADMA Biologics Inc (ADMA) vs SYSCO Corporation (SYY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs SYSCO Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while SYSCO Corporation trades at $83.11 (market cap $40.46B). The key difference: SYSCO Corporation is far larger — about 19× ADMA Biologics Inc's market cap, and SYSCO Corporation pays a 2.6% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | SYY | |
|---|---|---|
Market Cap | $2.13B | $40.46B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $91.16 |
52-Week Low | $7.60 | $69.30 |
Enterprise Value | $2.20B | $53.94B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Sysco (SYY) trades at $84.62, down 0.25% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains steady revenue growth, reaching $81.37B in 2025. Analyst consensus is a Buy with a $83.67 price target, supported by recent corporate developments including AI awards and World Cup supply chain preparations.
Outlook remains positive due to strong institutional support and strategic initiatives, though risks include margin pressure from rising costs and high debt levels. The stock's valuation metrics like P/E of 23.4 and P/S of 0.49 suggest reasonable pricing, but investors should monitor execution on future earnings and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
